Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Glaukos to $120 from $110 following the positive update from recent meeting with management and some multiple expansion in the high growth medtech peer group. The firm keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: